CAJ | 학술논문

目的：探讨分析紫杉醇联合奥沙利铂治疗复发性或晚期宫颈癌的临床疗效及不良反应。方法：选取北京同仁医院32例复发性或晚期宫颈癌，给予紫杉醇联合奥沙利铂化疗方案：第1天紫杉醇150 mg/m2静脉滴注≥3 h，第2天奥沙利铂130 mg/m2静脉滴注≥2 h，每21天为1个周期，治疗2个周期后进行评价，评估患者近远期疗效及不良反应。结果：全部患者均可参与评价疗效，总有效率为25.0%，中位无进展生存期（progression-free survival，PFS）和中位总生存期（overall survival，OS）分别为21.2周和52.1周。主要不良反应为神经毒性和骨髓抑制，非血液学不良反应较轻。结论：紫杉醇联合奥沙利铂治疗复发性或晚期宫颈癌患者疗效肯定，不良反应可以耐受，值得进一步临床研究。
목적：탐토분석자삼순연합오사리박치료복발성혹만기궁경암적림상료효급불량반응。방법：선취북경동인의원32례복발성혹만기궁경암，급여자삼순연합오사리박화료방안：제1천자삼순150 mg/m2정맥적주≥3 h，제2천오사리박130 mg/m2정맥적주≥2 h，매21천위1개주기，치료2개주기후진행평개，평고환자근원기료효급불량반응。결과：전부환자균가삼여평개료효，총유효솔위25.0%，중위무진전생존기（progression-free survival，PFS）화중위총생존기（overall survival，OS）분별위21.2주화52.1주。주요불량반응위신경독성화골수억제，비혈액학불량반응교경。결론：자삼순연합오사리박치료복발성혹만기궁경암환자료효긍정，불량반응가이내수，치득진일보림상연구。
Objective:To investigate the clinical efficacy and adverse reactions of paclitaxel plus oxaliplatin in the treatment of recurrent or advanced cervical cancer. Methods:32 patients of recurrent or advanced cervical cancer were given the chemotherapy of paclitaxel plus oxaliplatin :the dose of paclitaxel was 150 mg/m2 intravenous infusion≥3 h in the first day,and the dose of oxaliplatin was 130 mg/m2 intravenous infusion≥2 h in the second day,the course was repeated every 3 weeks,the evaluations of the short term or long term and adverse reactions were evaluated after 2 cycles treatment. Results:All patients can participate in the evaluation of curative effect,and the total effective rate was 25%. The median progression free survival and median overall survival were 21.2 weeks and 52.1 weeks respectively. The main adverse reactions were toxicities and myelosuppression,non-hematologic adverse reaction was mild. Conclusions:Paclitaxel plus oxaliplatin has quite valid curative effect on the treatment of recurrent or advanced cervical cancer patients,the adverse reactions can be tolerated,which was worthy for the further clinical research.